Cambrex Corporation (NYSE:CBM) has earned an average rating of “Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $64.00.
CBM has been the subject of several analyst reports. Zacks Investment Research raised Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 target price for the company in a research note on Thursday, May 11th. BidaskClub raised Cambrex Corporation from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Finally, ValuEngine cut Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd.
Shares of Cambrex Corporation (NYSE CBM) traded up 0.09% during midday trading on Monday, reaching $57.40. The company had a trading volume of 236,470 shares. The company’s 50 day moving average price is $55.04 and its 200-day moving average price is $54.10. Cambrex Corporation has a 52 week low of $38.30 and a 52 week high of $62.95. The company has a market capitalization of $1.87 billion, a P/E ratio of 21.85 and a beta of 2.42.
Cambrex Corporation (NYSE:CBM) last released its earnings results on Thursday, May 4th. The biotechnology company reported $0.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.17. Cambrex Corporation had a return on equity of 24.92% and a net margin of 17.36%. The firm had revenue of $105.01 million during the quarter, compared to analysts’ expectations of $99.05 million. During the same period in the previous year, the firm posted $0.50 EPS. Cambrex Corporation’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, equities research analysts predict that Cambrex Corporation will post $3.02 earnings per share for the current fiscal year.
In other news, Director Leon J. Hendrix, Jr. sold 20,656 shares of the company’s stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $55.95, for a total transaction of $1,155,703.20. Following the completion of the transaction, the director now directly owns 74,662 shares of the company’s stock, valued at approximately $4,177,338.90. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Samantha Hanley sold 14,000 shares of the company’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $57.56, for a total value of $805,840.00. Following the transaction, the vice president now directly owns 1,500 shares of the company’s stock, valued at $86,340. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 70,656 shares of company stock valued at $3,965,183. Insiders own 2.48% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Flinton Capital Management LLC boosted its position in Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 68 shares in the last quarter. YorkBridge Wealth Partners LLC boosted its position in Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 315 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Cambrex Corporation during the first quarter valued at about $109,000. Dubuque Bank & Trust Co. acquired a new position in Cambrex Corporation during the first quarter valued at about $144,000. Finally, Ameritas Investment Partners Inc. acquired a new position in Cambrex Corporation during the first quarter valued at about $151,000. 98.28% of the stock is owned by institutional investors and hedge funds.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2231086/cambrex-corporation-cbm-given-average-recommendation-of-buy-by-brokerages.html
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.